Vitamin D (Vit D) status is an emerging risk marker of great interest in cardiovascular
disease (CVD). Lower serum levels of Vit D are associated with both cardiac risk factors and
prevalent cardiovascular disease. Vit D insufficiency remains very prevalent in free living
populations in the United States especially in urban, and multi-ethnic low income Northern
cities.To date, prospective randomized trials using Vit D supplementation to modify CVD risk
and evaluate outcomes have not been performed.
The investigators propose a double-blind, randomized wait-list control trial in subjects with
Coronary Artery Disease (CAD) and Vit D deficiency with two specific aims. Specific aim 1 is
to measure endothelial function using reactive hyperemia peripheral arterial tonometry
(RH-PAT) before and after treatment with Vit D replacement therapy. Specific Aim 2 is to
measure levels of inflammation before and after treatment with Vit D replacement therapy.
These aims will test the hypotheses that Vit D repletion will improve endothelial function
and reduce the levels of detectable inflammation in the plasma of these subjects.
Phase:
N/A
Details
Lead Sponsor:
Seth I. Sokol, M.D.
Collaborators:
Albert Einstein College of Medicine Albert Einstein College of Medicine of Yeshiva University American Heart Association Jacobi Medical Center Montefiore Medical Center Yale University